Skip to main content

Advertisement

SpringerLink
Log in

Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy?

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

To analyze the expression of c-Met, and to investigate correlations between the expression of c-Met, clinicopathologic variables, and survival in patients undergoing curative surgery followed by adjuvant chemoradiotherapy for extrahepatic bile duct (EHBD) cancer.

Methods

Ninety EHBD cancer patients who underwent curative resection followed by adjuvant chemoradiotherapy were enrolled. Expression of c-Met was assessed with immunohistochemical staining on tissue microarray. The correlation between clinicopathologic variables and survival outcomes was evaluated using Kaplan–Meier method and Cox proportional hazard model.

Results

On univariate analysis, 66 patients (76.7 %) showed c-Met expression. c-Met expression had a significant impact on 5-year overall survival (OS) (43.0 % in c-Met(+) vs. 25.0 % in c-Met(−), p = 0.0324), but not on loco-regional relapse-free survival or distant metastasis-free survival (DMFS). However, on multivariate analysis incorporating tumor location and nodal involvement, survival difference was not maintained (p = 0.2940). Tumor location was the only independent prognostic factor predicting OS (p = 0.0089). Hilar location tumors, nodal involvement, and poorly differentiated tumors were all identified as independent prognostic factors predicting inferior DMFS (p = 0.0030, 0.0013, and 0.0037, respectively).

Conclusions

This study showed that c-Met expression was not associated with survival outcomes in EHBD cancer patients undergoing curative resection followed by adjuvant chemoradiotherapy. Further studies are needed to fully elucidate the prognostic value of c-Met expression in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14. doi:10.1016/S0140-6736(05)67530-7.

    Article  PubMed  Google Scholar 

  2. Socoteanu MP, Mott F, Alpini G, Frankel AE. c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 2008;14(19):2990–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98(2):418–25. doi:10.1038/sj.bjc.6604129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Huang XY, Ke AW, Shi GM, Ding ZB, Devbhandari RP, Gu FM, et al. Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients. Cancer. 2010;116(23):5440–51. doi:10.1002/cncr.25485.

    Article  CAS  PubMed  Google Scholar 

  5. Blumenschein GR Jr, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol. 2012;30(26):3287–96. doi:10.1200/JCO.2011.40.3774.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kim CH, Koh YW, Han JH, Kim JW, Lee JS, Baek SJ, et al. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck. 2010;32(12):1655–64. doi:10.1002/hed.21383.

    Article  PubMed  Google Scholar 

  7. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009;15(7):2207–14. doi:10.1158/1078-0432.CCR-08-1306.

    Article  CAS  PubMed  Google Scholar 

  8. Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J, et al. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 2007;98(7):1006–13. doi:10.1111/j.1349-7006.2007.00493.x.

    Article  CAS  PubMed  Google Scholar 

  9. Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, et al. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep. 2008;19(6):1477–83.

    PubMed  Google Scholar 

  10. Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, Raja S, Finkelstein S, Gooding W, et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia. 2005;7(1):75–84. doi:10.1593/neo.04367.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Liu C, Park M, Tsao MS. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene. 1992;7(1):181–5.

    CAS  PubMed  Google Scholar 

  12. Suzuki K, Hayashi N, Yamada Y, Yoshihara H, Miyamoto Y, Ito Y, et al. Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology. 1994;20(5):1231–6.

    Article  CAS  PubMed  Google Scholar 

  13. Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol. 1998;29(2):175–80.

    Article  CAS  PubMed  Google Scholar 

  14. Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y, et al. Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers. Oncol Rep. 1999;6(5):1051–6.

    CAS  PubMed  Google Scholar 

  15. Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology. 2002;40(3):269–78.

    Article  PubMed  Google Scholar 

  16. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005;206(3):356–65. doi:10.1002/path.1779.

    Article  CAS  PubMed  Google Scholar 

  17. Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 2011;105(1):131–8. doi:10.1038/bjc.2011.199.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res. 2009;15(2):660–7. doi:10.1158/1078-0432.CCR-08-1084.

    Article  CAS  PubMed  Google Scholar 

  19. Han Y, Zhang W, Liu Y. Identification of hepatoma-derived growth factor as a potential prognostic and diagnostic marker for extrahepatic cholangiocarcinoma. World J Surg. 2013;37(10):2419–27. doi:10.1007/s00268-013-2132-4.

    Article  PubMed  Google Scholar 

  20. Kim K, Min HS, Chie EK, Jang JY, Kim SW, Han SW, et al. CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. World J Gastroenterol. 2013;19(9):1438–43. doi:10.3748/wjg.v19.i9.1438.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Koh HK, Park HJ, Kim K, Chie EK, Min HS, Ha SW. Molecular biomarkers in extrahepatic bile duct cancer patients undergoing chemoradiotherapy for gross residual disease after surgery. Radiat Oncol J. 2012;30(4):197–204. doi:10.3857/roj.2012.30.4.197.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Uemura S, Kuramochi H, Higuchi R, Nakajima G, Yamamoto M. ERCC1 mRNA expression as a postoperative prognostic marker in extrahepatic bile duct cancer. Ann Surg Oncol. 2014. doi:10.1245/s10434-014-3726-2.

    Google Scholar 

  23. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002;36(2):439–50. doi:10.1053/jhep.2002.34435.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Hanyang University Hospital, Seoul, Republic of Korea

    H. J. Park

  2. Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea

    K. Kim, E. K. Chie, S. Kim & S. W. Ha

  3. Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea

    J. H. Paik

  4. Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea

    J.-Y. Jang & S. W. Kim

  5. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

    S.-W. Han, D.-Y. Oh, S.-A. Im, T.-Y. Kim & Y.-J. Bang

  6. Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea

    E. K. Chie & S. W. Ha

Authors
  1. H. J. Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. H. Paik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. K. Chie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J.-Y. Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. W. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S.-W. Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D.-Y. Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S.-A. Im
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T.-Y. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Y.-J. Bang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S. W. Ha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Kim.

Ethics declarations

Informed consent

Informed consent was obtained from all individual participants included in the study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Park, H.J., Kim, K., Paik, J.H. et al. Is c-Met oncoprotein expression an adverse prognosticator in extrahepatic bile duct cancer treated with curative resection followed by adjuvant chemoradiotherapy?. Clin Transl Oncol 18, 625–631 (2016). https://doi.org/10.1007/s12094-015-1409-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1409-5

Keywords

Search

Navigation